Emtricitabine/Tenofovir Disoproxil Fumarate Tablets

Camber Pharmaceuticals, Inc.

Revision date : 2022-01-18

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.
GHS05
Health risk rating 3
Safety risk rating 1
Environmental risk rating 1

General Information

Revision date

2022-01-18

Product name

Emtricitabine/Tenofovir Disoproxil Fumarate Tablets

Manufacturer Name

Hetero Labs Limited

Icons in SDS

GHS05

Company Information

company name

Camber Pharmaceuticals, Inc.

GHS Information

Signal word

US Hazard overview

Hazard Codes

Hazard statements (CLP)

H318

Hazard statements

Code

Statements

H318

Causes serious eye damage.

Section 2

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Drugs in the finished state and intended for the final user are not subject to labeling in the US, EU or Canada. Please consult the prescribing/packaging information. The classification and labelling listed below is for bulk Emtricitabine/Tenofovir Disoproxil Fumarate Tablets Regulation (EC)

CLP CLASSIFICATION

H318 - Causes serious eye damage.

Hazard statements

CLP/GHS precautionary P280 - Wear eye/face protection. P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P310 - Immediately call a Poison Center or doctor/ Physician Risk (R) Phrase(s) R41 - Risk of serious damage to eyes.

Precautionary statements

S2 - Keep out of reach of children. S25 - Avoid contact with eyes. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S39 - Wear eye/face protection.

2.3 Other hazards

Adverse effects seen with therapeutic use of Emtricitabine/Tenofovir Disoproxil Fumarate include diarrhea, nausea, abdominal pain, flatulence, pancreatitis, weakness, headache, dizziness, insomnia, abnormal dreams, allergic reactions, skin discoloration, rash, muscular weakness, bone problems, including bone pain, softening or thinning (which may lead to fractures), changes in immune system (Immune Reconstitution Syndrome). Serious effects including lactic acidosis, renal impairment, including cases of acute renal failure, and effects on the liver, including hepatomegaly and developing fat in liver. The recommended dose of Emtricitabine/Tenofovir Disoproxil Fumarate Tablets is one tablet per day (containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate)

Signal word

US Hazard overview Warning Causes eye irritation. Used as an antiretroviral agent for the treatment of HIV-1 infection.

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.